Idraparinux

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Idraparinux
Accession Number
DB06406
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
External IDs
SanOrg 34006 / SR 34006 / SR-34006
Product Ingredients
IngredientUNIICASInChI Key
Idraparinux SodiumH84IXP29FN149920-56-9Not applicable
Categories
UNII
6ADD3H8MFZ
CAS number
162610-17-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation.

Pharmacodynamics
Not Available
Mechanism of action

Idraparinux sodium is a novel long-acting synthetic highly potent synthetic and specific indirect inhibitor of coagulation factor Xa, injectable subcutaneously.

TargetActionsOrganism
UCoagulation factor XNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Idraparinux.
(R)-warfarinThe risk or severity of bleeding can be increased when Idraparinux is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Idraparinux is combined with (S)-Warfarin.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Idraparinux.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Idraparinux.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Idraparinux.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Idraparinux is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone4-Hydroxytestosterone may increase the anticoagulant activities of Idraparinux.
5beta-dihydrotestosterone5beta-dihydrotestosterone may increase the anticoagulant activities of Idraparinux.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Idraparinux.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Idraparinux

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedNot AvailableDeep Vein Thrombosis / Pulmonary Embolism1
3CompletedTreatmentAtrial Fibrillation (AF)1
3CompletedTreatmentDeep Vein Thrombosis1
3CompletedTreatmentDeep Venous Thrombosis1
3CompletedTreatmentPulmonary Embolism1
3CompletedTreatmentSystemic Embolism / Thrombotic events1
3TerminatedPreventionAtrial Fibrillation (AF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da

Drug created on March 19, 2008 10:29 / Updated on November 02, 2019 04:33